Revolutionary. A game-changer. Spine-chilling. Those are some of the words experts used to describe fresh data for lenacapavir, a twice-yearly shot developed by Gilead Sciences for the prevention of HIV.
Their enthusiasm stems from a more succinct word: zero. That is the number of cases of HIV that developed in the women and adolescent girls who received the drug in a huge study conducted across dozens of sites in South Africa and Uganda.
Lenacapavir has the potential to at long last move the needle on the incidence of HIV. The virus caused about 1.3 million infections and 630,000 deaths in 2022.
This preventive drug, if given to enough at-risk women, could be the way to get close to eliminating pediatric HIV, an expert said.
Another talked about finally bending infection curves in young women and adolescent girls, who account for 77 percent of new infections among younger people in sub-Saharan Africa.
However, none of that would happen without the right pieces in place to get the drug to everyone who needs it as soon as it receives regulatory clearance. That is an all-hands-on-deck effort that should be underway now.
Lenacapavir’s advantage is its unique mechanism and monthslong activity. While other HIV antivirals target enzymes the virus needs to replicate, lenacapavir takes aim at the capsid, an eggplant-shaped shell made up of hundreds of proteins that carefully assemble to protect the virus’ genetic material.
It turns out disrupting that shell works beautifully as a prophylaxis: In the trial, there were no HIV infections in the more than 2,100 women who received the drug, compared with infection rates of 1.5 percent and 1.8 percent in women taking Truvada or Descovy, two types of daily pills to prevent HIV infection (also known as PrEP).
“I’ve been doing this for almost 40 years, I have never, ever seen a result like this before,” Centre for the AIDS Programme of Research in South Africa director and infectious disease epidemiologist Salim Abdool Karim said. “To see a 100 percent efficacious product? It just blew my mind.”
The center enrolled several hundred women for the study, although Abdool Karim was not directly involved.
A separate prevention study of lenacapavir in men who have sex with men and transgender people is underway, after which Gilead plans to ask for regulatory approval. (The drug is already on the market in the US and elsewhere as a treatment for HIV.)
However, the data in young women are already extraordinary. The existing options for PrEP — whether daily pills, the dapivirine vaginal ring, or ViiV Healthcare’s bimonthly shot cabotegravir — have not moved the needle much on rates of infection among young women.
“A daily intervention needs a daily decision: ‘I’m going to protect myself,’” said Linda-Gail Bekker, director of the Desmond Tutu HIV Centre at the University of Cape Town and an investigator in the trial.
A wildly effective, twice-annual shot could make a huge difference in bending infection curves, particularly among women and infants.
Yet this astounding success can only come to fruition if lenacapavir reaches the people who need it. That comes down to access and delivery: Lenacapavir needs to be made at a volume that it can be widely available, at a price that makes it widely accessible and distributed in a way that makes it easy and appealing for everyone to stick with.
The ball is in Gilead’s court on the issues of price and supply. Gilead is, so far, saying all the right things.
The same day it revealed the astonishing trial results, the biotech company announced a two-pronged approach to ensuring lenacapavir can be widely available in places being hit hardest by HIV. It is to form license agreements that allow generic firms to make and sell the drug in low-resource countries hard hit by the HIV epidemic, a strategy used successfully in the past.
Until that generic supply is up and running, the company says it would set aside supply for those regions. That has elicited cautious optimism.
However, Gilead would also need to commit to transparency at every step of the process.
While the company has made substantial efforts to ensure people in low and middle-income countries can access its HIV therapies, it also has been criticized for some of its tactics around the price and development of certain medicines.
Global health experts would like to better understand which countries would have access to low-cost generic versions of the drug, and be assured that the company would work to transfer not only patents, but also know-how to ensure a speedy increase in manufacturing.
That third piece of the equation, delivery, would require a huge effort by global health agencies and their partners to study the most effective way to get the treatment to at-risk groups — not just once, of course, but every six months during the years they might be vulnerable to infection.
The work these groups have already done to provide existing forms of PrEP provides a good foundation for distributing lenacapavir, Unitaid senior strategy lead Carmen Perez Casas said. Meanwhile, studies would need to be quickly designed and funded to understand the best way to ensure broad and consistent use of the biannual shot.
This new drug, while astounding, does not obviate the need to keep pushing for an effective HIV vaccine. Yes, the new drug would likely meaningfully reduce infections (which also reduces transmission), but a vaccine that ideally can be administered before puberty is the key to eradicating this deadly virus.
Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, healthcare and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News.
Russian President Vladimir Putin’s hypersonic missile carried a simple message to the West over Ukraine: Back off, and if you do not, Russia reserves the right to hit US and British military facilities. Russia fired a new intermediate-range hypersonic ballistic missile known as “Oreshnik,” or Hazel Tree, at Ukraine on Thursday in what Putin said was a direct response to strikes on Russia by Ukrainian forces with US and British missiles. In a special statement from the Kremlin just after 8pm in Moscow that day, the Russian president said the war was escalating toward a global conflict, although he avoided any nuclear
Would China attack Taiwan during the American lame duck period? For months, there have been worries that Beijing would seek to take advantage of an American president slowed by age and a potentially chaotic transition to make a move on Taiwan. In the wake of an American election that ended without drama, that far-fetched scenario will likely prove purely hypothetical. But there is a crisis brewing elsewhere in Asia — one with which US president-elect Donald Trump may have to deal during his first days in office. Tensions between the Philippines and China in the South China Sea have been at
US President-elect Donald Trump has been declaring his personnel picks for his incoming Cabinet. Many are staunchly opposed to China. South Dakota Governor Kristi Noem, Trump’s nomination to be his next secretary of the US Department of Homeland Security, said that since 2000, China has had a long-term plan to destroy the US. US Representative Mike Waltz, nominated by Trump to be national security adviser, has stated that the US is engaged in a cold war with China, and has criticized Canada as being weak on Beijing. Even more vocal and unequivocal than these two Cabinet picks is Trump’s nomination for
An article written by Uber Eats Taiwan general manager Chai Lee (李佳穎) published in the Liberty Times (sister paper of the Taipei Times) on Tuesday said that Uber Eats promises to engage in negotiations to create a “win-win” situation. The article asserted that Uber Eats’ acquisition of Foodpanda would bring about better results for Taiwan. The National Delivery Industrial Union (NDIU), a trade union for food couriers in Taiwan, would like to express its doubts about and dissatisfaction with Lee’s article — if Uber Eats truly has a clear plan, why has this so-called plan not been presented at relevant
RSS